N- succinimidyl- 3- (2- pyridyldithio)butyrate

Also Known As:
Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Lambert, John M: 2 articles (07/2015 - 05/2011)
2. Goldmacher, Victor S: 2 articles (07/2015 - 05/2011)
3. Singh, Rajeeva: 2 articles (07/2015 - 05/2011)
4. Morilak, David A: 1 article (09/2015)
5. Boley, Angela M: 1 article (09/2015)
6. Jett, Julianne D: 1 article (09/2015)
7. Shah, Amiksha: 1 article (09/2015)
8. Lodge, Daniel J: 1 article (09/2015)
9. Girotti, Milena: 1 article (09/2015)
10. Payne, Gillian: 1 article (07/2015)

Related Diseases

1. Neoplasms (Cancer)
07/01/2015 - "We compared M9346A conjugates with various linker/maytansinoid combinations, and found that a conjugate, now denoted as IMGN853, with the N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB) linker and N(2')-deacetyl-N(2')-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4) exhibited the most potent antitumor activity in several FRĪ±-expressing xenograft tumor models. "
02/01/1993 - "The therapeutic efficacy of SWAII-SPDB-dg.ricin A chain was further demonstrated by the selective elimination of clonogenic SW2 cells from small tumor-cell deposits established in sponge matrices. "
02/01/1993 - "The cytotoxic potency of SWAII-SPDB-dg.ricin A chain was demonstrated in tissue culture by the inhibition of 3H-leucine incorporation and by the selective elimination of CD24-positive tumor cells in clonogenic assays. "
05/26/2011 - "Antibody-maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly against multidrug resistant (MDR) cancer cell lines in vitro and tumor xenograft models in vivo."
02/01/1993 - "In nude mice, SWAII-SPDB-dg.ricin A chain was cleared from the blood circulation with biphasic kinetics: an initial alpha phase of 1 hr and a second beta phase of 20.5 hr. Following i.v. injection of a dose equivalent to 30% of the LD50, the immunotoxin delayed the growth of SW2 solid-tumor xenografts by 16 days. "
2. Small Cell Lung Carcinoma (Small Cell Lung Cancer)
3. Shock

Related Drugs and Biologics

1. Immunotoxins (Immunotoxin)
2. Ricin
3. Butyrates (Butyrate)
4. Surface Antigens (Surface Antigen)
5. Antigens
6. Abrin
7. cibacron blue-sepharose

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)